Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006222 · ClinicalTrials.gov registry record · Phase 1
EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00006222: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00006222 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006222, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of EMD 121974 in treating patients who have HIV-related Kaposi's sarcoma. EMD 121974 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
Interventions
- DRUG cilengitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-09 |
| Est. Completion | 2001-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006222
The ClinicalTrials.gov registry entry for NCT00006222 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cilengitide is the first listed.
NCT00006222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006222 about?
NCT00006222 is a clinical study titled "EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma". Phase I trial to study the effectiveness of EMD 121974 in treating patients who have HIV-related Kaposi's sarcoma. EMD 121974 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
What is the current status of trial NCT00006222?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2000-09. Estimated completion is 2001-03.
What interventions are being tested in trial NCT00006222?
The interventions under investigation include: cilengitide (DRUG).
Who is sponsoring clinical trial NCT00006222?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.